David Bowkett; Romain Talon; Cynthia Tallant; Chris Schofield; Frank von Delft; Stefan Knapp; Gordon Bruton; Paul E. Brennan
Index: 10.1002/cmdc.201800030
Full Text: HTML
Epigenetics is a rapidly growing field in drug discovery. Of particular interest is the role of post‐translational modifications to histones and the proteins that read, write, and erase such modifications. The development of inhibitors for reader domains has focused on single domains. One of the major difficulties of designing inhibitors for reader domains is that, with the notable exception of bromodomains, they tend not to possess a well‐enclosed binding site amenable to small‐molecule inhibition. As many of the proteins in epigenetic regulation have multiple domains, there are opportunities for designing inhibitors that bind at a domain–domain interface which provide a more suitable interaction pocket. Examination of X‐ray structures of multiple domains involved in recognising and modifying post‐translational histone marks using the SiteMap algorithm identified potential binding sites at domain–domain interfaces. For the tandem plant homeodomain–bromodomain of SP100C, a potential inter‐domain site identified computationally was validated experimentally by the discovery of ligands by X‐ray crystallographic fragment screening.
Fluorinated GluN2B Receptor Antagonists with a 3‐Benzazepine...
2018-04-17 [10.1002/cmdc.201700819] |
Synthesis, Pharmacological Evaluation, and Docking Studies o...
2018-04-16 [10.1002/cmdc.201800152] |
Discovery of Benzimidazole–Quinolone Hybrids as New Cleaving...
2018-04-16 [10.1002/cmdc.201700739] |
Transthyretin Mimetics as Anti‐β‐Amyloid Agents: A Compariso...
2018-04-16 [10.1002/cmdc.201800031] |
Antibody Epitope of Human α‐Galactosidase A Revealed by Affi...
2018-04-16 [10.1002/cmdc.201800094] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved